Real-Word Data on Long-Term Outcomes Among Adult Patients With Myopericarditis Related Heart Failure
Author(s)
Shanthi Krishnaswami, MBBS, MPH1, Manu Tyagi, MBA2, Zhun Cao, PhD2;
1Premier Inc., Principal Research Scientist, Charlotte, NC, USA, 2Premier Inc, Charlotte, NC, USA
1Premier Inc., Principal Research Scientist, Charlotte, NC, USA, 2Premier Inc, Charlotte, NC, USA
Presentation Documents
OBJECTIVES: Real-world evidence on long-term outcomes of myocarditis/pericarditis (MPC) associated heart failure (HF) is limited. This research aims to assess clinical and economic outcomes of MPC-HF in the year after first discharge.
METHODS: Adult inpatients with a primary diagnosis of HF and concurrent diagnosis of MPC during 1/2019- 6/2023 with a one-year follow-up were analyzed in this retrospective cohort study utilizing data from the Premier Healthcare Database (large, all-payer, US hospital administrative) and general mortality database. Propensity score matched cohorts were created to compare clinical, economic outcomes and healthcare utilization at index and in the year after first MPC-HF discharge.
RESULTS: Among 87,819 inpatients with a diagnosis of HF, the prevalence of MPC was 2.9% (with median age 60 years, 49.6% male, Black: 17.7%), while HF patients without MPC (non-MPCHF) accounted for 97% of hospitalizations. After matching for potential confounders including severity of condition, 2,544 (MPC-HF) and 7,624 (non-MPCHF) patients were analyzed. At index, dilated cardiomyopathy, arrythmia, mechanical ventilation and heart transplantation were significantly associated with MPC-HF (OR range: 1.2 to 2.68, p<0.01). MPC-HF patients stayed significantly longer in the hospital and in intensive care unit (ICU) and incurred higher median hospital cost than non-MPCHF patients ($12,771 vs. $11,238, p<0.001). The death rates at index discharge were similar (17%) between the two cohorts. Within one year after index discharge, MPC-HF was significantly associated with increased odds of pericardiocentesis (OR: 3.5, p=0.02) and heart transplantation (OR: 1.98, p<0.001). Both cohorts had similar death and readmission rates. However, MPC-HF patients had significantly longer ICU length of stay (mean: MPC-HF: 9.8 days vs. non-MPCHF:6.6 days, p<0.001), and higher median ICU cost (MPC-HF: $11,003 vs. non-MPCHF: $8,485, p<0.001) than non-MPCHF patients.
CONCLUSIONS: This study highlights that myocarditis/pericarditis, was associated with increased long-term morbidity, cost and higher utilization of healthcare services in patients with HF.
METHODS: Adult inpatients with a primary diagnosis of HF and concurrent diagnosis of MPC during 1/2019- 6/2023 with a one-year follow-up were analyzed in this retrospective cohort study utilizing data from the Premier Healthcare Database (large, all-payer, US hospital administrative) and general mortality database. Propensity score matched cohorts were created to compare clinical, economic outcomes and healthcare utilization at index and in the year after first MPC-HF discharge.
RESULTS: Among 87,819 inpatients with a diagnosis of HF, the prevalence of MPC was 2.9% (with median age 60 years, 49.6% male, Black: 17.7%), while HF patients without MPC (non-MPCHF) accounted for 97% of hospitalizations. After matching for potential confounders including severity of condition, 2,544 (MPC-HF) and 7,624 (non-MPCHF) patients were analyzed. At index, dilated cardiomyopathy, arrythmia, mechanical ventilation and heart transplantation were significantly associated with MPC-HF (OR range: 1.2 to 2.68, p<0.01). MPC-HF patients stayed significantly longer in the hospital and in intensive care unit (ICU) and incurred higher median hospital cost than non-MPCHF patients ($12,771 vs. $11,238, p<0.001). The death rates at index discharge were similar (17%) between the two cohorts. Within one year after index discharge, MPC-HF was significantly associated with increased odds of pericardiocentesis (OR: 3.5, p=0.02) and heart transplantation (OR: 1.98, p<0.001). Both cohorts had similar death and readmission rates. However, MPC-HF patients had significantly longer ICU length of stay (mean: MPC-HF: 9.8 days vs. non-MPCHF:6.6 days, p<0.001), and higher median ICU cost (MPC-HF: $11,003 vs. non-MPCHF: $8,485, p<0.001) than non-MPCHF patients.
CONCLUSIONS: This study highlights that myocarditis/pericarditis, was associated with increased long-term morbidity, cost and higher utilization of healthcare services in patients with HF.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD64
Topic
Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)